Privia Health Group (PRVA) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.19
- Estimate
- $0.24
- Surprise
- -22.2%
- Revenue (period 2026-06-30)
- $632.6M
- Score today
- 6.1/10
Revenue source: xbrl.
How the report landed
Privia Health Group (PRVA) missed the $0.24 estimate with diluted EPS of $0.19 — a large 22.2% shortfall.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PRVA Sell at 6.1/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's -22.2% surprise compares with a +4.4% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Quality below floor (3.9 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.88
- Price target
- $28.50
- Stop
- $19.76
- Upside to target
- +36.5%
- Reward-to-risk
- 6.8:1
The stock trades at 92.8× trailing but 19.2× forward earnings — consensus estimates already build in a substantial earnings recovery.
Model outputs from TrendMatrix’s engine as of 2026-09-15 — shown for context, not personalized investment advice.
PRVA at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Health Information Services
- Market cap
- $2.61B
- P/E (fwd)
- 19.2
- P/E (ttm)
- 92.8
- 52-week range
- $19.53–$28.82
- Off 52-week high
- 27.6%
- RSI (14)
- 47
- Volume vs avg
- 1.30×
- Score today
- 6.1/10